Stay updated on Rapid Test & Treat Dolutegravir Plus Lamivudine Clinical Trial
Sign up to get notified when there's something new on the Rapid Test & Treat Dolutegravir Plus Lamivudine Clinical Trial page.

Latest updates to the Rapid Test & Treat Dolutegravir Plus Lamivudine Clinical Trial page
- Check3 days agoChange DetectedThe footer revision changed from v3.7.2 to v3.8.0 while the study page continued to display a 403 Forbidden error.SummaryDifference0.2%

- Check10 days agoChange DetectedA sitewide notice about NIH’s transition from “Artificial Intelligence” to “Super Intelligence” appears above the study record page.SummaryDifference1%

- Check17 days agoChange DetectedThe footer’s revision label changed from v3.7.1 to v3.7.2 on the 403 Forbidden page.SummaryDifference0.2%

- Check24 days agoChange DetectedThe site revision changed from v3.7.0 to v3.7.1. The page still displays a 403 error instead of the study record.SummaryDifference0.2%

- Check45 days agoChange DetectedThe page now displays a 403 Forbidden error for the study record, replacing the expected content with an access-denied error page.SummaryDifference19%

- Check65 days agoChange DetectedThe page shows an updated revision version from v3.6.5 to v3.6.6, indicating a small internal update. This update does not modify the study details, eligibility criteria, or other user-visible content.SummaryDifference0.0%

Stay in the know with updates to Rapid Test & Treat Dolutegravir Plus Lamivudine Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Rapid Test & Treat Dolutegravir Plus Lamivudine Clinical Trial page.